Eurofins Clinical Testing Holding LUX SARL completed the acquisition of GeneTech Inc. from Noritsu Koki Co., Ltd..
September 31, 2020
Share
Eurofins Clinical Testing Holding LUX SARL entered into an agreement to acquire GeneTech Inc. from Noritsu Koki Co., Ltd. (TSE:7744) on August 7, 2020. Noritsu Koki Co., Ltd. will sell 0.14 million shares of GeneTech Inc. As a result of the share transfer, GeneTech Inc. will no longer be a consolidated subsidiary of Noritsu Koki Co., Ltd. For the year ending March 31, 2020, GeneTech Inc. reported net assets of ¥2.19 billion, total assets of ¥2.4 billion, net sales of ¥1.36 billion, operating income of ¥392 million and net income of ¥262 million. The transaction has been approved by the Board of Directors of Noritsu Koki Co., Ltd. on August 7, 2020 and is expected to complete on August 31, 2020.
Eurofins Clinical Testing Holding LUX SARL completed the acquisition of GeneTech Inc. from Noritsu Koki Co., Ltd. (TSE:7744) on September 1, 2020. Taro Okayama of Oaklins’ team in Japan acted as the exclusive financial advisor to Noritsu Koki Co., Ltd. in this transaction.
Noritsu Koki Co., Ltd. is a company principally engaged in the manufacturing business, healthcare business and other businesses. The Company operates in six business segments. The Manufacturing segment is engaged in the research, development and manufacture of pen nib parts and cosmetics materials, among others. The Healthcare segment is engaged in the research, development and sale of radiological business support services by remote diagnostic imaging in the healthcare area, the analysis of received data and the provision of survey data, among others. The Drug Discovery segment develops new products in biotechnology area. The Senior and Life segment conducts senior publishing and mail order sales business. The Agri-food segment conducts the production and sale of fresh vegetables in the agri-food field. The Others segment conducts new growth related survey and investment business.
NORITSU KOKI CO., LTD. 
